Clinical Trial Evidence for Ozempic, Wegovy & Mounjaro
Understanding Ozempic vs Wegovy vs Mounjaro Weight Loss Results
The confusion between Ozempic, Wegovy, and Mounjaro often stems from overlapping active ingredients and marketing messages, but the clinical evidence tells a clear story. Wegovy (semaglutide) is specifically licensed for weight management in adults with BMI ≥30, or BMI ≥27 with weight-related conditions, while Ozempic contains the same active ingredient but is licensed exclusively for type 2 diabetes treatment. Mounjaro (tirzepatide) represents a dual GIP and GLP-1 receptor agonist, offering a different mechanism of action compared to Wegovy's GLP-1-only approach.
The weight loss results from clinical trials demonstrate distinct outcomes for each prescription-only medicine. In the STEP 1 trial, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). Mounjaro's SURMOUNT-1 trial showed different percentage outcomes, though direct comparison isn't appropriate due to varying trial designs and participant populations.
Wegovy Pricing Structure and Bundle Options for UK Patients
EverydayMeds offers transparent pricing for Wegovy across all dose escalation stages, with new customers applying discount code FIRST40 at checkout and returning customers using DOSE25. The starter dose of 0.25mg costs £79.99, progressing through 0.5mg at £94.99, 1mg at £99.99, 1.7mg at £139.99, and the maintenance 2.4mg dose at £209.99. Our Getting Started bundles provide convenient multi-dose options, including the Intro Duo (0.25mg & 0.5mg) for £169.99 and Progress Duo (0.5mg & 1mg) for £189.99.
The Step-Up bundles cater to patients planning their complete dose escalation journey, with the Intro Trio (0.25mg, 0.5mg & 1mg) available for £299.99 and the Progress Trio (0.5mg, 1mg & 1.7mg) for £369.99. For patients requiring consistent dosing, our Stay Steady bundles offer multiple pens of the same strength, such as Consistency 2.4mg (×2) for £419.99, ensuring uninterrupted treatment at maintenance doses.
STEP Trial Clinical Evidence for Ozempic Wegovy Mounjaro Comparisons
The published STEP trial programme provides robust evidence for Wegovy's weight management efficacy in real clinical settings. STEP 3 demonstrated approximately 16% average weight loss when Wegovy was combined with intensive behavioural therapy, while STEP 5 showed sustained results of around clinically studied weight loss maintained at 2 years. The SELECT cardiovascular outcomes trial further revealed a 20% reduction in major cardiovascular events among participants taking semaglutide.
These clinical trial results represent outcomes achieved alongside a reduced-calorie diet and increased physical activity, not standalone medication effects. Individual results may vary significantly from trial averages, and weight management requires long-term commitment beyond the medication period, as STEP 1 extension data showed participants regained approximately two-thirds of weight lost within one year of discontinuing treatment.
How Wegovy Works Differently from Ozempic and Mounjaro
Wegovy functions as a GLP-1 receptor agonist, mimicking the natural incretin hormone GLP-1 that your body produces after eating. This mechanism reduces appetite by acting on brain appetite centres, promotes feelings of fullness after smaller meals, and may help reduce food cravings throughout the day. Unlike Ozempic, which uses the same semaglutide ingredient but targets diabetes management, Wegovy is specifically formulated and licensed for weight management applications. Mounjaro operates through a dual mechanism, targeting both GIP and GLP-1 receptors, which may influence both glucose regulation and appetite control through complementary pathways.
EverydayMeds Ordering Process for Ozempic Wegovy Mounjaro
Our streamlined ordering process begins with a comprehensive 3-minute online clinical assessment, covering your medical history, current medications, and weight management goals. A qualified prescriber reviews your assessment within 3 working days (or 24 hours with express service), ensuring Wegovy is clinically appropriate for your individual circumstances. Once approved, your prescription-only medicine is dispatched via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. All orders are processed through our GPhC-registered pharmacy (#9012878), ensuring full regulatory compliance and pharmaceutical standards. Patient support continues throughout your treatment journey, with our clinical team available for dosing guidance and medication queries.
Storage and Practical Considerations for Wegovy vs Mounjaro
Wegovy requires refrigeration at 2-8°C before first use, but offers superior travel flexibility compared to Mounjaro, remaining stable at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration versus Mounjaro's 21-day room temperature limit. The FlexTouch pen delivery system provides consistent dosing with clear visual confirmation of injection completion, while the mandatory dose escalation schedule (0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg) helps minimise gastrointestinal side effects. Each pen contains multiple doses depending on the strength, with the 2.4mg maintenance pen providing approximately one month of once-weekly injections. Proper disposal through pharmacy take-back schemes ensures environmental responsibility and medication security.
Real-World Weight Loss Outcomes: Ozempic Wegovy Mounjaro UK Data
Beyond clinical trial environments, real-world evidence from UK weight management clinics suggests that patient outcomes with Wegovy and Mounjaro can vary significantly based on adherence, lifestyle modifications, and individual metabolic factors. The NICE guidance (TA875) recommends these medications alongside specialist weight management support, recognising that optimal results require comprehensive care beyond medication alone. Healthcare providers report that patients who engage with structured dietary counselling and regular physical activity monitoring tend to achieve outcomes closer to clinical trial averages.
Patient-reported outcome measures from UK clinical practice indicate that both Wegovy and Mounjaro users experience reduced food preoccupation and improved portion control within the first month of treatment. However, gastrointestinal adaptation varies considerably, with some patients requiring slower dose escalation or temporary dose holds to manage side effects effectively.
Choosing Between Wegovy and Mounjaro: Clinical Decision Factors
The decision between Wegovy and Mounjaro should always involve clinical assessment of your individual circumstances, medical history, and treatment preferences rather than simple outcome comparisons. Both medications are available from EverydayMeds following appropriate prescriber evaluation, with your clinician considering factors such as previous GLP-1 exposure, concurrent medications, and specific health conditions. Cost considerations, storage requirements, and injection frequency may also influence the most suitable choice for your lifestyle and treatment goals. Our prescribers provide detailed counselling about realistic expectations, potential side effects, and long-term treatment planning to support informed decision-making throughout your weight management journey.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
